The Indian generics firm, Indoco, has outlined a string of new initiatives to build its presence in the growing chronic and lifestyle disease segments, including a new division focused on cardiology and diabetes backed by a field force of more than 200 personnel and a string of proposed new launches.
The company told Scrip that the new division, Indoco CND (care in cardiology and diabetology), will begin with a revenue...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
